Intra-Cellular Therapies, Inc. Board of Directors

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Dr. Sharon Mates Ph.D.

Dr. Sharon Mates Ph.D.

Co-Founder, Chairman & CEO

Dr. Suresh K. Durgam M.D.

Dr. Suresh K. Durgam M.D.

Executive VP & Chief Medical Officer

Mr. Juan Fernando Sanchez M.D.

Mr. Juan Fernando Sanchez M.D.

Vice President of Corporate Communications & Investor Relations

Mr. Mark Neumann

Mr. Mark Neumann

EVP & Chief Commercial Officer

Dr. Michael Olchaskey

Dr. Michael Olchaskey

Senior VP & Head of Regulatory Affairs

Dr. Robert E. Davis Ph.D.

Dr. Robert E. Davis Ph.D.

Senior VP & Chief Scientific Officer

John P. Condon

John P. Condon

Senior Vice President, General Counsel & Secretary

Mr. Sanjeev Narula

Mr. Sanjeev Narula

Executive VP & CFO

Ms. Karen Patruno Sheehy Esq.

Ms. Karen Patruno Sheehy Esq.

Senior VP & Chief Compliance Officer

Comments